Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3. / Sabbah, Muhammad; Veien, Karsten; Niemela, Matti; Freeman, Phillip; Linder, Rickard; Ioanes, Dan; Terkelsen, Christian Juhl; Kajander, Olli A.; Koul, Sasha; Savontaus, Mikko; Karjalainen, Pasi; Erglis, Andrejs; Minkkinen, Mikko; Jørgensen, Troels; Sondergaard, Lars; De Backer, Ole; Engstrøm, Thomas; Lønborg, Jacob.
In: American Heart Journal, Vol. 255, 2023, p. 39-51.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Routine revascularization with percutaneous coronary intervention in patients with coronary artery disease undergoing transcatheter aortic valve implantation – the third nordic aortic valve intervention trial – NOTION-3
AU - Sabbah, Muhammad
AU - Veien, Karsten
AU - Niemela, Matti
AU - Freeman, Phillip
AU - Linder, Rickard
AU - Ioanes, Dan
AU - Terkelsen, Christian Juhl
AU - Kajander, Olli A.
AU - Koul, Sasha
AU - Savontaus, Mikko
AU - Karjalainen, Pasi
AU - Erglis, Andrejs
AU - Minkkinen, Mikko
AU - Jørgensen, Troels
AU - Sondergaard, Lars
AU - De Backer, Ole
AU - Engstrøm, Thomas
AU - Lønborg, Jacob
N1 - Funding Information: This study was funded by an unrestricted grant from Boston Scientific for investigator-initiated trials and a grant from the Danish Heart Foundation (17-R116-A7697-22073). The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents. Publisher Copyright: © 2022 The Author(s)
PY - 2023
Y1 - 2023
N2 - Background: Coronary artery disease (CAD) frequently coexists with severe aortic valve stenosis (AS) in patients planned for transcatheter aortic valve implantation (TAVI). How to manage CAD in this patient population is still an unresolved question. In particular, it is still not known whether fractional flow reserve (FFR) guided revascularization with percutaneous coronary intervention (PCI) is superior to medical treatment for CAD in terms of clinical outcomes. Study design: The third Nordic Aortic Valve Intervention (NOTION-3) Trial is an open-label investigator-initiated, multicenter multinational trial planned to randomize 452 patients with severe AS and significant CAD to either FFR-guided PCI or medical treatment, in addition to TAVI. Patients are eligible for the study in the presence of at least 1 significant PCI-eligible coronary stenosis. A significant stenosis is defined as either FFR ≤0.80 and/or diameter stenosis >90%. The primary end point is a composite of first occurring all-cause mortality, myocardial infarction, or urgent revascularization (PCI or coronary artery bypass graft performed during unplanned hospital admission) until the last included patient have been followed for 1 year after the TAVI. NOTION-3 is a multicenter, multinational randomized trial aiming at comparing FFR-guided revascularization vs medical treatment of CAD in patients with severe AS planned for TAVI.
AB - Background: Coronary artery disease (CAD) frequently coexists with severe aortic valve stenosis (AS) in patients planned for transcatheter aortic valve implantation (TAVI). How to manage CAD in this patient population is still an unresolved question. In particular, it is still not known whether fractional flow reserve (FFR) guided revascularization with percutaneous coronary intervention (PCI) is superior to medical treatment for CAD in terms of clinical outcomes. Study design: The third Nordic Aortic Valve Intervention (NOTION-3) Trial is an open-label investigator-initiated, multicenter multinational trial planned to randomize 452 patients with severe AS and significant CAD to either FFR-guided PCI or medical treatment, in addition to TAVI. Patients are eligible for the study in the presence of at least 1 significant PCI-eligible coronary stenosis. A significant stenosis is defined as either FFR ≤0.80 and/or diameter stenosis >90%. The primary end point is a composite of first occurring all-cause mortality, myocardial infarction, or urgent revascularization (PCI or coronary artery bypass graft performed during unplanned hospital admission) until the last included patient have been followed for 1 year after the TAVI. NOTION-3 is a multicenter, multinational randomized trial aiming at comparing FFR-guided revascularization vs medical treatment of CAD in patients with severe AS planned for TAVI.
U2 - 10.1016/j.ahj.2022.10.009
DO - 10.1016/j.ahj.2022.10.009
M3 - Journal article
C2 - 36220354
AN - SCOPUS:85140977677
VL - 255
SP - 39
EP - 51
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
ER -
ID: 370115003